Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I/II Study to Evaluate the Feasibility and Efficacy of Sequential Abemaciclib and Gemcitabine Treatment in Patients With Retinoblastoma (Rb)+ Sarcomas

NCT06498648 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.

NCT NCT06498648
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06498648 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I/II Study to Evaluate the Feasibility and Efficacy of Sequential Abemaciclib and Gemcitabine Treatment in Patients With Retinoblastoma (Rb)+ Sarcomas
Lead sponsor
National Cancer Institute (NCI)
Phase
Phase 1/2
Overall status
Recruiting
Start date
March 18, 2026
Completion date
January 31, 2027
Enrollment
74 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

advanced dedifferentiated liposarcoma, advanced leiomyosarcoma, advanced soft tissue sarcoma, metastatic dedifferentiated liposarcoma, metastatic leiomyosarcoma, metastatic soft tissue sarcoma, stage iii soft tissue sarcoma of the trunk and extremities ajcc v8, stage iv soft tissue sarcoma of the trunk and extremities ajcc v8